Omentin-1 vs Linaclotide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Linaclotide (Linaclotide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Linaclotide |
|---|---|---|
| Category | Diabetes & Metabolic | Gastrointestinal |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Linaclotide |
| Molecular Weight | ~35 kDa | 1526.8 Da |
| Half-Life | hours | Active locally; negligible systemic half-life |
| Amino Acids | 313 | 14 |
| Typical Dose | No approved human dose; research use only | 72-290 mcg once daily |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 1200 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
Omentin-1 Dosing
not established|not established
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.